Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.48
IMMU's Cash-to-Debt is ranked lower than
88% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. IMMU: 0.48 )
Ranked among companies with meaningful Cash-to-Debt only.
IMMU' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.33  Med: N/A Max: No Debt
Current: 0.48
Equity-to-Asset -1.40
IMMU's Equity-to-Asset is ranked lower than
97% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IMMU: -1.40 )
Ranked among companies with meaningful Equity-to-Asset only.
IMMU' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.78  Med: 0.77 Max: 0.97
Current: -1.4
-1.78
0.97
Piotroski F-Score: 2
Altman Z-Score: -11.21
Beneish M-Score: -3.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -2012.48
IMMU's Operating Margin % is ranked lower than
84% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. IMMU: -2012.48 )
Ranked among companies with meaningful Operating Margin % only.
IMMU' s Operating Margin % Range Over the Past 10 Years
Min: -2012.48  Med: -289.05 Max: 55.69
Current: -2012.48
-2012.48
55.69
Net Margin % -2385.59
IMMU's Net Margin % is ranked lower than
85% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. IMMU: -2385.59 )
Ranked among companies with meaningful Net Margin % only.
IMMU' s Net Margin % Range Over the Past 10 Years
Min: -2385.59  Med: -212.6 Max: 60.72
Current: -2385.59
-2385.59
60.72
ROA % -117.46
IMMU's ROA % is ranked lower than
87% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. IMMU: -117.46 )
Ranked among companies with meaningful ROA % only.
IMMU' s ROA % Range Over the Past 10 Years
Min: -117.46  Med: -32.8 Max: 74.44
Current: -117.46
-117.46
74.44
ROC (Joel Greenblatt) % -1760.69
IMMU's ROC (Joel Greenblatt) % is ranked lower than
70% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. IMMU: -1760.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IMMU' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2222.63  Med: -422.27 Max: 760.43
Current: -1760.69
-2222.63
760.43
3-Year Revenue Growth Rate -19.00
IMMU's 3-Year Revenue Growth Rate is ranked lower than
74% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. IMMU: -19.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IMMU' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -56.9  Med: -0.8 Max: 81.6
Current: -19
-56.9
81.6
3-Year EBITDA Growth Rate 66.30
IMMU's 3-Year EBITDA Growth Rate is ranked higher than
94% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. IMMU: 66.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IMMU' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -28.1  Med: 1.3 Max: 111.8
Current: 66.3
-28.1
111.8
3-Year EPS without NRI Growth Rate 60.50
IMMU's 3-Year EPS without NRI Growth Rate is ranked higher than
92% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. IMMU: 60.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IMMU' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -36.3  Med: -5.6 Max: 100
Current: 60.5
-36.3
100
GuruFocus has detected 5 Warning Signs with Immunomedics Inc $IMMU.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IMMU's 10-Y Financials

Financials (Next Earnings Date: 2017-05-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

IMMU Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
» More
Q2 2016

IMMU Guru Trades in Q2 2016

Jim Simons 1,772,807 sh (New)
» More
Q3 2016

IMMU Guru Trades in Q3 2016

Jim Simons Sold Out
» More
Q4 2016

IMMU Guru Trades in Q4 2016

Steven Cohen 68,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with IMMU

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325413    SIC: 2835
Compare:NAS:CYTK, NAS:LJPC, NAS:ANAB, NAS:ANIP, NAS:ACHN, NAS:AUPH, NAS:XBIT, NAS:SPPI, NAS:RGNX, NAS:ENTA, NAS:ACIU, NAS:NTLA, NAS:RETA, NAS:ATRA, NAS:ARDX, NAS:CARA, NAS:AMRI, NAS:INO, NAS:VNDA, OTCPK:SPHDF » details
Traded in other countries:IM3.Germany,
Headquarter Location:USA
Immunomedics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

Immunomedics Inc was incorporated in Delaware in 1982. It is a biopharmaceutical company, which develops monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It has developed proprietary technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or 'naked' form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create targeted agents. Using these technologies, it has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Its product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, the Company is planning to launch a Phase III pivotal trial for clivatuzumab labeled with a radioisotope in pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development includes two antibody-drug conjugates sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). DNL is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. It has licensed its product candidate, epratuzumab, to UCB S.A., or UCB, for the treatment of all autoimmune disease indications. It manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, and it currently reports as a single industry segment. Its geographic locations include United States and Europe. It competes with Biogen Idec, Roche, GlaxoSmithKline, Seattle Genetics, ImmunoGen Merck Serono, Genmab, Celgene, Amgen, Bristol-Myers Squibb, Bayer Healthcare Pharmaceuticals, Pfizer, AstraZeneca and Eli Lilly, are engaged in the development of therapeutic autoimmune and oncology products. Its patents include approximately 267 active patents in the U.S. and more than 400 other issued patents all over the world. Its research and development activities, including testing in laboratory animals and in humans, its manufacture of antibodies, as well as the handling, labeling and storage of the product candidates that the company is developing, are all subject to stringent regulation, by the FDA in the U.S. and by comparable authorities in other countries.

Ratios

vs
industry
vs
history
PS Ratio 175.51
IMMU's PS Ratio is ranked lower than
91% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. IMMU: 175.51 )
Ranked among companies with meaningful PS Ratio only.
IMMU' s PS Ratio Range Over the Past 10 Years
Min: 2.96  Med: 29.53 Max: 221.94
Current: 175.51
2.96
221.94
EV-to-EBIT -11.47
IMMU's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. IMMU: -11.47 )
Ranked among companies with meaningful EV-to-EBIT only.
IMMU' s EV-to-EBIT Range Over the Past 10 Years
Min: -343.7  Med: -7.1 Max: 298.3
Current: -11.47
-343.7
298.3
EV-to-EBITDA -11.63
IMMU's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. IMMU: -11.63 )
Ranked among companies with meaningful EV-to-EBITDA only.
IMMU' s EV-to-EBITDA Range Over the Past 10 Years
Min: -226.2  Med: -7.3 Max: 393.3
Current: -11.63
-226.2
393.3
Current Ratio 1.69
IMMU's Current Ratio is ranked lower than
78% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. IMMU: 1.69 )
Ranked among companies with meaningful Current Ratio only.
IMMU' s Current Ratio Range Over the Past 10 Years
Min: 0.6  Med: 5.1 Max: 38
Current: 1.69
0.6
38
Quick Ratio 1.67
IMMU's Quick Ratio is ranked lower than
74% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. IMMU: 1.67 )
Ranked among companies with meaningful Quick Ratio only.
IMMU' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 4.96 Max: 37.93
Current: 1.67
0.59
37.93
Days Inventory 113.40
IMMU's Days Inventory is ranked higher than
56% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. IMMU: 113.40 )
Ranked among companies with meaningful Days Inventory only.
IMMU' s Days Inventory Range Over the Past 10 Years
Min: 113.4  Med: 310.77 Max: 938.67
Current: 113.4
113.4
938.67
Days Sales Outstanding 23.21
IMMU's Days Sales Outstanding is ranked higher than
82% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. IMMU: 23.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
IMMU' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.57  Med: 24.8 Max: 105.77
Current: 23.21
2.57
105.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.00
IMMU's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. IMMU: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IMMU' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.6  Med: -5.3 Max: -0.1
Current: -5
-14.6
-0.1

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 5.91
IMMU's Price-to-Median-PS-Value is ranked lower than
96% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. IMMU: 5.91 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IMMU' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 1.24 Max: 7.34
Current: 5.91
0.11
7.34
Earnings Yield (Greenblatt) % -8.72
IMMU's Earnings Yield (Greenblatt) % is ranked lower than
56% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. IMMU: -8.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IMMU' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9.34  Med: 5 Max: 18.5
Current: -8.72
-9.34
18.5

More Statistics

Revenue (TTM) (Mil) $2.96
EPS (TTM) $ -0.71
Beta2.90
Short Percentage of Float26.77%
52-Week Range $1.95 - 7.15
Shares Outstanding (Mil)106.08
» More Articles for IMMU

Headlines

Articles On GuruFocus.com
Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients With Metastatic Small-Ce Apr 05 2017 
Immunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Delivery With Labetuzumab Apr 04 2017 
Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Ch Apr 04 2017 
Immunomedics Inc. Reports Operating Results (10-Q) Feb 04 2011 
Immunomedics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Immunomedics Inc. Reports Operating Results (10-K) Aug 26 2010 
Fastest Growing Magic Formula Stocks: Jiangbo Pharmaceuticals, DragonWave, Immunomedics, Genoptix, P Jul 15 2010 
Immunomedics Inc. Reports Operating Results (10-Q) May 10 2010 
Immunomedics Inc. Reports Operating Results (10-Q) Feb 02 2010 
Immunomedics Inc. Reports Operating Results (10-Q) Nov 06 2009 

More From Other Websites
Immunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : April 25, 2017 Apr 25 2017
Immunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : April 24, 2017 Apr 24 2017
Why Immunomedics, Inc. Got Hammered Today Apr 21 2017
Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients With Metastatic... Apr 05 2017
Immunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Delivery With Labetuzumab... Apr 04 2017
Biotech Movers: Paratek Spikes 34% Apr 04 2017
Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome... Apr 04 2017
Battle in the Boardroom: What's Next for Immunomedics Mar 28 2017
Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and Immunomedics Mar 28 2017
Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017 Mar 28 2017
Billionaires' Best Healthcare Stock Picks of 2017 (So Far) Mar 21 2017
3 Companies That Need to Kick Their CEO to the Curb Mar 17 2017
Biotech Premarket Movers: Arena, Immunomedics, Aralez Mar 15 2017
Immunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating... Mar 15 2017
Here’s What’s Moving Immunomedics, Inc. (IMMU) And Ocera Therapeutics Inc (OCRX) Mar 10 2017
Judge Blocks $2B Immunomedics-Seattle Genetics Deal (IMMU,SGEN) Mar 10 2017
Markets Rally Late to Close in the Green: Today's Research Reports on Immunomedics and VIVUS Mar 10 2017
Why Immunomedics, Inc. Jumped Higher Today Mar 09 2017
Why Marathon Oil, Signet Jewelers, and Immunomedics Jumped Today Mar 09 2017
Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted Mar 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)